Business
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
NEW YORK--(BUSINESS WIRE)-- Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announced that it
About this update from Aptorum Group Limited
[{"type":"text","content":" NEW YORK--(BUSINESS WIRE)--\nAptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company it is approved to transfer the listing of its Class A ordinary shares, from the Nasdaq Global Market to the Nasdaq Capital Market. On this basis, the previous two listing deficiencies regarding minimum stockholder’s equity and minimum market value of publicly held shares will be closed. The trading of its Class A ordinary shares will continue on Nasdaq and will not be affected. \n\n\nAbout Aptorum Group\n\n\nAptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications), autoimmune and infectious diseases. Aptorum has completed two phase I clinical trials for its ALS-4 (MRSA) and orphan drug designated SACT-1 (Neuroblastoma) small molecule drugs and commercializing its NLS-2 NativusWell® nutraceutical (menopause). The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases; and (ii) the co-development and ongoing clinical validation of its novel molecular-based rapid pathogen identification and detection diagnostics technology with Singapore’s Agency for Science, Technology and Research.\n\n\nFor more information about the Company, please visit www.aptorumgroup.com.\n\n\nDisclaimer and Forward-Looking Statements\n\n\nThis press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.\n\n\nThis press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forw...